Fulcrum Therapeutics, Inc. $FULC Shares Acquired by Suvretta Capital Management LLC

Suvretta Capital Management LLC increased its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 5.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,381,000 shares of the company’s stock after buying an additional 298,100 shares during the period. Suvretta Capital Management LLC owned about 0.10% of Fulcrum Therapeutics worth $49,505,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in FULC. Russell Investments Group Ltd. lifted its stake in Fulcrum Therapeutics by 4,209.3% in the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock worth $64,000 after acquiring an additional 9,092 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Fulcrum Therapeutics by 108.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after purchasing an additional 3,697 shares in the last quarter. Assetmark Inc. purchased a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth $88,000. Los Angeles Capital Management LLC acquired a new position in shares of Fulcrum Therapeutics during the second quarter worth $93,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Fulcrum Therapeutics in the third quarter valued at $104,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Royal Bank Of Canada lifted their price target on Fulcrum Therapeutics from $7.00 to $10.00 and gave the stock a “sector perform” rating in a report on Monday, December 8th. Leerink Partners reiterated an “outperform” rating on shares of Fulcrum Therapeutics in a report on Tuesday, February 24th. The Goldman Sachs Group reissued a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th. Stifel Nicolaus set a $25.00 target price on Fulcrum Therapeutics in a research note on Monday, December 8th. Finally, HC Wainwright upped their price target on Fulcrum Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Monday, December 8th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Insider Activity

In related news, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $11.87, for a total value of $178,050.00. Following the completion of the sale, the director directly owned 469,864 shares of the company’s stock, valued at $5,577,285.68. This represents a 3.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.00% of the stock is currently owned by company insiders.

Fulcrum Therapeutics Price Performance

Shares of FULC opened at $7.65 on Friday. Fulcrum Therapeutics, Inc. has a 1-year low of $2.32 and a 1-year high of $15.74. The stock has a market cap of $509.49 million, a PE ratio of -6.48 and a beta of 3.23. The firm has a fifty day moving average price of $9.83 and a 200 day moving average price of $9.58.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.31). As a group, equities analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.